Profile data is unavailable for this security.
About the company
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
- Revenue in USD (TTM)140.39m
- Net income in USD101.33m
- Incorporated1999
- Employees29.00
- LocationSCYNEXIS Inc1 Evertrust Plaza, 13Th FloorJERSEY CITY 07302-6548United StatesUSA
- Phone+1 (201) 884-5485
- Fax+1 (919) 544-8697
- Websitehttps://www.scynexis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spero Therapeutics Inc | 110.98m | 23.40m | 73.42m | 46.00 | 3.23 | 0.7612 | 3.10 | 0.6616 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 75.10m | 47.00 | -- | 1.88 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 76.28m | 9.00 | -- | 3.87 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Bioatla Inc | 0.00 | -119.24m | 76.50m | 65.00 | -- | 1.54 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| MDxHealth SA - ADR | 75.33m | -39.90m | 76.68m | 300.00 | -- | -- | -- | 1.02 | -1.14 | -1.14 | 0.8428 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.54 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Precision BioSciences Inc | 57.53m | -19.99m | 77.01m | 109.00 | -- | 2.07 | -- | 1.34 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 77.07m | 29.00 | 1.01 | 1.04 | -- | 0.549 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Journey Medical Corp | 80.00m | -4.16m | 78.05m | 58.00 | -- | 8.57 | -- | 0.9757 | -0.3095 | -0.3095 | 4.13 | 0.6498 | 0.985 | 2.27 | 4.28 | 1,379,276.00 | -5.12 | -- | -17.85 | -- | 66.22 | -- | -5.20 | -- | 0.9357 | 0.4049 | 0.5773 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 78.12m | 23.00 | -- | -- | -- | 1,148.86 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -120.23m | 78.50m | 168.00 | -- | 0.6376 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Chimerix Inc | 41.00k | -82.59m | 78.65m | 72.00 | -- | 0.4518 | -- | 1,918.30 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Genelux Corp | 8.00k | -25.78m | 79.94m | 23.00 | -- | 4.16 | -- | 9,992.16 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 80.48m | 165.00 | -- | -- | -- | 2.84 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
Data as of Jun 14 2024. Currency figures normalised to SCYNEXIS Inc's reporting currency: US Dollar USD
32.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 4.21m | 11.16% |
| Kingdon Capital Management LLCas of 31 Mar 2024 | 2.24m | 5.92% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.68m | 4.45% |
| Avidity Partners Management LPas of 31 Mar 2024 | 1.45m | 3.84% |
| AMH Equity Ltd.as of 31 Mar 2024 | 660.00k | 1.75% |
| D.A. Davidson & Co. (Investment Management)as of 31 Mar 2024 | 524.47k | 1.39% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 421.08k | 1.12% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 395.91k | 1.05% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 356.24k | 0.94% |
| Geode Capital Management LLCas of 31 Mar 2024 | 355.21k | 0.94% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
